I last covered Roivant Sciences Ltd. (NASDAQ:ROIV) in a note for Seeking Alpha back in May last year, giving the company a buy recommendation, based on an intriguing and differentiated drug development pipeline targeting multi-billion dollar indications, with multiple significant data catalysts in play. 10 months on, Roivant stock has made a slight gain of ~10%, and shown minimal volatility, despite some significant developments at the company.